ArticlePediatric blood & cancer2011
Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006.
Article in Pediatric blood & cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 93 citations in OpenAlex.
- Safety and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Trial
- Approach to the Preoperative Pharmacological Management of Catecholamine-Secreting Tumors in Children: A Case Series and Review.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children.European journal of nuclear medicine and molecular imaging · 2025Observational
- Investigation of an oncolytic herpes simplex virus as a potential therapeutic agent for gastroenteropancreatic neuroendocrine neoplasms.Scientific reports · 2025Article
- Endoscopic Submucosal Resection With a Ligation Device for Pediatric Rectal Neuroendocrine Tumor.ACG case reports journal · 2025Article
- Gastroenteropancreatic neuroendocrine neoplasms in children and adults: a comparative review.Frontiers in endocrinology · 2025Review
- Liver metastasized pancreatic neuroendocrine tumor in a 17-year-old female: A case report.Clinical case reports · 2024Article
- Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors.Translational oncology · 2024Article
- Alpha-emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor.Pediatric blood & cancer · 2024Article
- Gastroenteropancreatic neuroendocrine carcinoma in children and adolescents: a population-based study.Journal of cancer research and clinical oncology · 2024Article
- Palbociclib releases the latent differentiation capacity of neuroblastoma cells.Developmental cell · 2023Article
- Imaging of pediatric abdominal soft tissue tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.Pediatric blood & cancer · 2023Article
- Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors.Frontiers in nuclear medicine · 2023Article
- Using 3D-bioprinted models to study pediatric neural crest-derived tumors.International journal of bioprinting · 2023Article
- Review
- International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.Ecancermedicalscience · 2022Article
- Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report.Frontiers in neuroscience · 2022Article
- Hypoglycemia secondary to insulinoma masking the onset of type 1 diabetes in an adolescent.Clinical case reports · 2021Article
- A rare case of severe hypertension with hypokalemic metabolic alkalosis in a 14-year-old girl: Answers.Pediatric nephrology (Berlin, Germany) · 2020Article
- Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe incidence, survival, and prevalence of neuroendocrine tumors (NETs) in children were determined as a first step in improving diagnosis and therapy. Outcomes were compared with neuroblastoma, a pediatric malignancy that shares several biomarkers.
methodsIncidence rates, observed survival rates and 31-year limited duration prevalence counts were obtained from SEER*Stat for diagnosis years 1975 to 2006. These rates were compared between and within NETs and neuroblastoma for demographic and tumor-related variables from nine standard SEER registries for ages 0-29 years. Multivariate Cox regression was performed to identify prognostic factors for survival in NETs.
resultsThe number of NETs was 1,073 compared to 1,664 neuroblastomas. The most common NET sites were lung, breast, and appendix. NET 5-year observed survival rates increased from 83% between 1975 and 1979 to 84% for the 2000-2006 period, while analogous neuroblastoma survival rates steadily increased from 45-73%. Five-year observed survival was less than 30% in females with NETs of the cervix and ovary. The estimated 31-year limited duration prevalence for NETs as of January 1, 2006 in the U.S. population was 7,724 compared to 9,960 for neuroblastomas. Age-adjusted multivariate Cox Regression demonstrated small cell histology, primary location in the breast, and distant stage as major predictors of decreased survival.
conclusionsWhile survivorship has significantly increased for neuroblastoma, those diagnosed with NETs have shown no increase in survival during this 31-year period. NETs constitute an unrecognized cancer threat to children and young adults comparable to neuroblastoma in both number of affected persons and disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.